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Background: There is still a sore need for better characterization of 
factors inﬂuencing survival in speciﬁc subgroups and in individual 
patients with NSCLC. RRM1 is involved in DNA repair, Tdp1 is impli-
cated in the repair of CPT-induced topoisomerase damage, and NFAT 
promotes cancer invasion. BubR1 is a key spindle checkpoint gene, and 
altered BubR1 mRNA levels are associated with lymph node metastasis 
and chromosome instability. 
Methods: The expression of these four genes was identiﬁed in frozen 
resected tumors from 126 resected NSCLC p by real-time quantitative 
PCR. Gene expression was normalized using a-actin expression as 
internal reference. 
Results: Adenocarcinoma (adeno), 33 p; squamous cell carcinoma 
(SCC), 93 p. Stage: IA, 18 p; IB, 53 p; IIB, 33 p; IIIA, 22 p. Tumor 
transcript expression: RRM1, 2.10; Tdp1, 1.77; NFAT, 0.56; BubR1, 
16.40. Expression of RRM1, Tdp1 and BubR1 was higher in SCC than 
in adeno (P<0.001). Median time to relapse (TTR) was longer for p 
with low levels of RRM1 (P=0.11), Tdp1 (P=0.86), NFAT (P=0.29), 
or BubR1 (P=0.44). A signiﬁcant trend towards longer survival was 
observed in stage I p with low RRM1 P=0.06). In a multivariate Cox 
model, tumor size > 4 cm and stage III predicted shorter TTR and 
survival. 
Conclusion: Increased mRNA expression of these genes might be 
associated with shorter survival; this knowledge could be useful for 
customizing adjuvant chemotherapy.
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Is there still a place for surgery in the treatment of locally 
advanced non-small cell lung cancer (IIIA, N2)?
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Background: Surgical resection for patients with stage IIIA (N2) non-
small cell lung cancer (NSCLC) results in disappointing 5-year survival 
rates (<10%). Most of these patients develop distant metastases, and 
this rationalizes the use of induction chemotherapy. There is ongoing 
discussion about the role of surgical resection (vs. radiotherapy) as 
local treatment modality after induction therapy. The aim of this retro-
spective analysis was to evaluate results of surgery and radiotherapy 
after neoadjuvant chemotherapy in the clinical setting. 
Methods: Patients with stage IIIA NSCLC treated with neoadjuvant 
chemotherapy from 1994 tot 2006 were identiﬁed from the cancer reg-
istration databases. During this period every treatment proposal or trial 
participation was discussed within a multidisciplinary thoracic oncol-
ogy committee. Response to induction therapy, deﬁnitive local therapy, 
recurrence of disease, and overall survival were reviewed. 
Results: Ninety-nine patients, 66 men and 33 women, were identiﬁed. 
The mean age was 61 (36-77), 40 tumors were left-sided. Neoadjuvant 
chemotherapy consisted of platin-based doublets/triplets. Clinical me-
diastinal downstaging was achieved in 32 patients. Thirty-nine patients 
underwent surgery, 19 lobectomies and 19 pneumonectomies were 
performed and one thoracotomy without resection. Forty-two patients 
received radiotherapy with radical intent. Nineteen patients received 
palliative treatment. 
Microscopic complete resection was achieved in 26 patients (69%). 
Histopathological response to induction therapy was complete (n=2), 
partial (n=23), or stable disease (n=13). The 2- and 5-year overall 
survival after surgery was 58% and 29% respectively, survival in lo-
bectomy patients being signiﬁcantly higher (p=0.03; ﬁg 1a+b). Surgical 
complications were infectious (n=4) or cardiovascular (n=7), mostly 
after pneumonectomy. The postoperative mortality was 3% (n=1, after 
pneumonectomy). 
Radiation doses actually delivered in patients with intended radical 
schemes ranged from 51 to 81 Gy, median dose given was 60 Gy. Grade 
3-4 radiation toxicity was seen in 10 patients. The 2- and 5-year overall 
survival after radiotherapy was 37% and 16% respectively (ﬁg 1a).
Conclusions: Radiotherapy is being regarded as the standard local 
treatment modality after neoadjuvant chemotherapy for stage IIIA 
NSCLC. Our retrospective data conﬁrm, that in selected patients com-
plete surgical resection (lobectomy) is also associated with long-term 
survival and cure.
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